The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have s...

Descripción completa

Detalles Bibliográficos
Autores principales: Aragón-Herrera, Alana, Otero-Santiago, Manuel, Anido-Varela, Laura, Moraña-Fernández, Sandra, Campos-Toimil, Manuel, García-Caballero, Tomás, Barral, Luis, Tarazón, Estefanía, Roselló-Lletí, Esther, Portolés, Manuel, Gualillo, Oreste, Moscoso, Isabel, Lage, Ricardo, González-Juanatey, José Ramón, Feijóo-Bandín, Sandra, Lago, Francisca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847595/
https://www.ncbi.nlm.nih.gov/pubmed/35185578
http://dx.doi.org/10.3389/fphar.2022.827033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847595/
https://www.ncbi.nlm.nih.gov/pubmed/35185578
http://dx.doi.org/10.3389/fphar.2022.827033

Ejemplares similares